These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

303 related items for PubMed ID: 18387067

  • 21. Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy.
    Schwarz B, Gouveia M, Chen J, Nocea G, Jameson K, Cook J, Krishnarajah G, Alemao E, Yin D, Sintonen H.
    Diabetes Obes Metab; 2008 Jun; 10 Suppl 1():43-55. PubMed ID: 18435673
    [Abstract] [Full Text] [Related]

  • 22. Long-term cost-consequence analysis of exenatide once weekly vs sitagliptin or pioglitazone for the treatment of type 2 diabetes patients in the United States.
    Guillermin AL, Lloyd A, Best JH, DeYoung MB, Samyshkin Y, Gaebler JA.
    J Med Econ; 2012 Jun; 15(4):654-63. PubMed ID: 22369345
    [Abstract] [Full Text] [Related]

  • 23. Sex and BMI Alter the Benefits and Risks of Sulfonylureas and Thiazolidinediones in Type 2 Diabetes: A Framework for Evaluating Stratification Using Routine Clinical and Individual Trial Data.
    Dennis JM, Henley WE, Weedon MN, Lonergan M, Rodgers LR, Jones AG, Hamilton WT, Sattar N, Janmohamed S, Holman RR, Pearson ER, Shields BM, Hattersley AT, MASTERMIND Consortium.
    Diabetes Care; 2018 Sep; 41(9):1844-1853. PubMed ID: 30072404
    [Abstract] [Full Text] [Related]

  • 24. Cost-effectiveness of saxagliptin vs glimepiride as a second-line therapy added to metformin in Type 2 diabetes in China.
    Gu S, Deng J, Shi L, Mu Y, Dong H.
    J Med Econ; 2015 Sep; 18(10):808-20. PubMed ID: 25950193
    [Abstract] [Full Text] [Related]

  • 25. Preventing Unnecessary Costs of Drug-Induced Hypoglycemia in Older Adults with Type 2 Diabetes in the United States and Canada.
    Boulin M, Diaby V, Tannenbaum C.
    PLoS One; 2016 Sep; 11(9):e0162951. PubMed ID: 27648831
    [Abstract] [Full Text] [Related]

  • 26. Pioglitazone versus rosiglitazone treatment in patients with type 2 diabetes and dyslipidemia: cost-effectiveness in the US.
    Tunis SL, Minshall ME, St Charles M, Pandya BJ, Baran RW.
    Curr Med Res Opin; 2008 Nov; 24(11):3085-96. PubMed ID: 18826750
    [Abstract] [Full Text] [Related]

  • 27. Cost-effectiveness of rosiglitazone oral combination for the treatment of type 2 diabetes in Germany.
    Shearer AT, Bagust A, Liebl A, Schoeffski O, Goertz A.
    Pharmacoeconomics; 2006 Nov; 24 Suppl 1():35-48. PubMed ID: 16800161
    [Abstract] [Full Text] [Related]

  • 28. Reducing the Burden of Diabetes Treatment: A Review of Low-cost Oral Hypoglycemic Medications.
    Vaughan EM, Rueda JJ, Samson SL, Hyman DJ.
    Curr Diabetes Rev; 2020 Nov; 16(8):851-858. PubMed ID: 32026779
    [Abstract] [Full Text] [Related]

  • 29. Cost-effectiveness of second-line antihyperglycemic therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin.
    Klarenbach S, Cameron C, Singh S, Ur E.
    CMAJ; 2011 Nov 08; 183(16):E1213-20. PubMed ID: 21969406
    [Abstract] [Full Text] [Related]

  • 30. Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: impact on cardiovascular events. A randomized controlled trial.
    Vaccaro O, Masulli M, Bonora E, Del Prato S, Giorda CB, Maggioni AP, Mocarelli P, Nicolucci A, Rivellese AA, Squatrito S, Riccardi G, TOSCA.IT study group (Thiazolidinediones Or Sulphonylureas and Cardiovascular Accidents. Intervention Trial).
    Nutr Metab Cardiovasc Dis; 2012 Nov 08; 22(11):997-1006. PubMed ID: 23063367
    [Abstract] [Full Text] [Related]

  • 31. Cost-effectiveness of dipeptidyl peptidase-4 inhibitor monotherapy versus sulfonylurea monotherapy for people with type 2 diabetes and chronic kidney disease in Thailand.
    Permsuwan U, Dilokthornsakul P, Thavorn K, Saokaew S, Chaiyakunapruk N.
    J Med Econ; 2017 Feb 08; 20(2):171-181. PubMed ID: 27645706
    [Abstract] [Full Text] [Related]

  • 32. Race, ethnicity, and use of thiazolidinediones among US adults with diabetes.
    Aquilante CL, Zhang W, McCollum M.
    Curr Med Res Opin; 2007 Mar 08; 23(3):489-94. PubMed ID: 17355730
    [Abstract] [Full Text] [Related]

  • 33. Cost-effectiveness of dapagliflozin (Forxiga®) added to metformin compared with sulfonylurea added to metformin in type 2 diabetes in the Nordic countries.
    Sabale U, Ekman M, Granström O, Bergenheim K, McEwan P.
    Prim Care Diabetes; 2015 Feb 08; 9(1):39-47. PubMed ID: 24840612
    [Abstract] [Full Text] [Related]

  • 34. Long-term clinical and economic outcomes associated with liraglutide versus sitagliptin therapy when added to metformin in the treatment of type 2 diabetes: a CORE Diabetes Model analysis.
    Lee WC, Samyshkin Y, Langer J, Palmer JL.
    J Med Econ; 2012 Feb 08; 15 Suppl 2():28-37. PubMed ID: 22834986
    [Abstract] [Full Text] [Related]

  • 35. Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial.
    Umpierrez G, Issa M, Vlajnic A.
    Curr Med Res Opin; 2006 Apr 08; 22(4):751-9. PubMed ID: 16684436
    [Abstract] [Full Text] [Related]

  • 36. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial.
    Vaccaro O, Masulli M, Nicolucci A, Bonora E, Del Prato S, Maggioni AP, Rivellese AA, Squatrito S, Giorda CB, Sesti G, Mocarelli P, Lucisano G, Sacco M, Signorini S, Cappellini F, Perriello G, Babini AC, Lapolla A, Gregori G, Giordano C, Corsi L, Buzzetti R, Clemente G, Di Cianni G, Iannarelli R, Cordera R, La Macchia O, Zamboni C, Scaranna C, Boemi M, Iovine C, Lauro D, Leotta S, Dall'Aglio E, Cannarsa E, Tonutti L, Pugliese G, Bossi AC, Anichini R, Dotta F, Di Benedetto A, Citro G, Antenucci D, Ricci L, Giorgino F, Santini C, Gnasso A, De Cosmo S, Zavaroni D, Vedovato M, Consoli A, Calabrese M, di Bartolo P, Fornengo P, Riccardi G, Thiazolidinediones Or Sulfonylureas Cardiovascular Accidents Intervention Trial (TOSCA.IT) study group, Italian Diabetes Society.
    Lancet Diabetes Endocrinol; 2017 Nov 08; 5(11):887-897. PubMed ID: 28917544
    [Abstract] [Full Text] [Related]

  • 37. Comparison of costs and outcomes of dapagliflozin with other glucose-lowering therapy classes added to metformin using a short-term cost-effectiveness model in the US setting.
    Chakravarty A, Rastogi M, Dhankhar P, Bell KF.
    J Med Econ; 2018 May 08; 21(5):497-509. PubMed ID: 29376760
    [Abstract] [Full Text] [Related]

  • 38. The effect of pioglitazone as add-on therapy to metformin or sulphonylurea compared to a fixed-dose combination of metformin and glibenclamide on diabetic dyslipidaemia.
    Comaschi M, Corsi A, Di Pietro C, Bellatreccia A, Mariz S, COM06 Study Investigators.
    Nutr Metab Cardiovasc Dis; 2008 Jun 08; 18(5):373-9. PubMed ID: 17919894
    [Abstract] [Full Text] [Related]

  • 39. Applying some UK Prospective Diabetes Study results to Switzerland: the cost-effectiveness of intensive glycaemic control with metformin versus conventional control in overweight patients with type-2 diabetes.
    Palmer AJ, Sendi PP, Spinas GA.
    Schweiz Med Wochenschr; 2000 Jul 11; 130(27-28):1034-40. PubMed ID: 10953853
    [Abstract] [Full Text] [Related]

  • 40. Pioglitazone, rosiglitazone, and rosiglitazone + metformin: new drugs. Glitazone + oral antidiabetic combination: inadequately evaluated.
    Prescrire Int; 2005 Aug 11; 14(78):133-9. PubMed ID: 16106595
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.